---

Patient Summary & Prescription Analysis

Clinical Presentation Recap

• Chief complaints: Finger stiffness (right hand), right leg pain, burning sensation in both lower legs/feet — duration 1 year
• Pattern: Worsens at night, associated with tingling and numbness in feet
• Known comorbidity: Bronchial asthma (on medication)
• Negative history: No DM, HTN, thyroid disorders
• Social history: Ex-smoker (quit 2 years ago)
• Vitals: BP 110/70 mmHg, PR 88 bpm (afebrile)

---

Likely Working Diagnoses (from the prescription pattern)

1. Peripheral Neuropathy (burning, tingling, numbness in bilateral lower limbs worsening at night)
2. Inflammatory arthritis / early Rheumatoid Arthritis (finger stiffness, night worsening)
3. Bronchial Asthma (known, on treatment)
4. The Ri- (rule in/out) mentions Status Asthmaticus and Renovascular HTN in evaluation — likely differentials being worked up

---

Prescription Breakdown

---

Clinical Correlation

---

Key Clinical Notes

• Peripheral neuropathy in a non-diabetic patient with no thyroid disease — the workup should include Vitamin B12 levels, serum uric acid, RA factor, ANA, nerve conduction study (NCS/EMG), and CBC to rule out nutritional deficiency, inflammatory arthritis, or vasculitis-related neuropathy.
• Night worsening of stiffness is a classic inflammatory pattern, pointing toward early Rheumatoid Arthritis — RA factor, anti-CCP antibody testing is warranted.
• Optineuron (Methylcobalamin 1500 mcg + B-complex) IV is appropriate first-line for symptomatic B12 deficiency neuropathy.
• Ceftriaxone usage here may suggest a concurrent infection or a pre-treatment protocol, though its indication should be confirmed with cultures/CRP/ESR.
• Losartan 25 mg at a BP of 110/70 needs monitoring — if BP drops further, dose may need reassessment.
• PCM was appropriately crossed out — possibly due to concern for masking fever or hepatic caution.

---

⚠️ Note: This analysis is for clinical academic purposes. All treatment decisions must be made by the treating physician based on complete clinical assessment and investigations.

---

Side Effects, Adverse Effects & Drug-Drug Interactions

---

1. Inj. Monocef (Ceftriaxone 1g IV OD)

---

2. Inj. Optineuron (Methylcobalamin + B-complex IV)

---

3. Tab. Librium (Chlordiazepoxide 10 mg)

---

4. Inj. PAN (Pantoprazole 40 mg IV OD)

---

5. Inj. Zofer (Ondansetron 4 mg IV TID)

---

6. Tab. Losartan 25 mg OD

---

7. Tab. Derophylline (Doxophylline 150 mg BD)

---

8. Tab. Levocetirizine 5 mg OD

---

9. Nebulisation: Duolin (Ipratropium + Salbutamol) + Budecort (Budesonide)

---

Critical Drug Combinations to Flag in This Prescription

---

⚠️ This information is for clinical academic reference. All drug decisions must be supervised by the treating physician and pharmacist.

• Is it a specific drug name (e.g., Brufen, Penicillin, Aspirin)?
• Or a type of reaction (e.g., rash, swelling, breathing difficulty)?

1) Key learning points from this case

• Pattern suggests chronic peripheral neuropathic pain: burning feet, tingling, numbness, night worsening for 1 year.
• Possible coexisting inflammatory/rheumatologic condition: finger stiffness (especially if morning stiffness is prolonged).
• Asthma is active and being treated aggressively (doxophylline + nebulization + antihistamine).
• Polypharmacy risk is present: multiple IV and oral drugs with overlapping adverse-effect profiles.

2) Most important side effects/adverse effects in this prescription

• Chlordiazepoxide (Librium): sedation, cognitive slowing, falls risk, dependence with prolonged use.
• Doxophylline/xanthine class: palpitations, insomnia, nausea, and at higher exposure arrhythmia/seizure risk.
• Losartan: hypotension, dizziness, hyperkalemia, renal function changes.
• Ondansetron: constipation, headache, QT prolongation risk.
• Ceftriaxone: diarrhea, allergy, biliary sludge, C. difficile risk.
• Pantoprazole: long-term B12/magnesium reduction, infection risk (C. difficile).
• Nebulized salbutamol/ipratropium: tremor, tachycardia, dry mouth, urinary retention (susceptible patients).

3) Clinically relevant drug-drug interaction risks to flag

• Librium + Levocetirizine: additive CNS depression/sedation.
• Librium + other sedating agents: increased drowsiness/fall risk.
• Doxophylline + beta-agonist (salbutamol in Duolin): additive tachycardia/palpitations.
• Doxophylline + certain antibiotics (if added later, especially macrolides/quinolones): toxicity risk increases.
• Losartan + NSAIDs (if prescribed for pain): reduced BP effect + kidney risk.
• Losartan + potassium supplements/K-sparing diuretics: hyperkalemia risk.
• Ceftriaxone + broad GI risk context: watch for antibiotic-associated diarrhea.

4) What to suggest to doctors (practical, high-value)

1. Confirm diagnosis before continuing symptomatic polypharmacy
   • Neuropathy workup: CBC, HbA1c/fasting glucose, B12, TSH, renal/liver profile, ESR/CRP, NCS if needed.
   • For finger stiffness: RA factor, anti-CCP, uric acid, X-ray/small joint exam as indicated.
2. Medication rationalization
   • Reassess need for ceftriaxone if no infection evidence.
   • Reassess duration/need of Librium; avoid long-term use if possible.
   • Continue neuropathy-directed therapy but define endpoint and follow-up response.
3. Safety monitoring plan
   • BP, creatinine, potassium (with losartan).
   • ECG/HR if palpitations or high bronchodilator/xanthine exposure.
   • Sedation/fall assessment due to CNS depressant combination.
   • Bowel symptoms and C. difficile warning if diarrhea develops.
4. Asthma optimization
   • Check inhaler/nebulization technique.
   • Prefer guideline-based controller strategy and step-up/step-down plan.
   • Review whether doxophylline is still necessary once control improves.
5. Pain/neuropathy strategy
   • If persistent neuropathic pain, consider guideline-based agents (for example pregabalin/duloxetine/gabapentin depending on profile), rather than prolonged sedative use.
   • Foot care counseling and sleep hygiene.

5) What you can say in case presentation

• "This appears to be chronic neuropathic lower-limb pain with possible inflammatory small-joint involvement and coexisting asthma. Current regimen controls symptoms but carries sedation, cardiovascular, and interaction risks. Recommend targeted etiological workup and deprescribing/rationalization with active monitoring."

---

WARD ROUND NOTE

---

PATIENT SUMMARY

• Stiffness in fingers (right hand)
• Pain in right leg
• Burning sensation in both lower legs and feet
• Tingling and numbness in feet
• All symptoms since 1 year, worsening at night
• Sleep disturbance
• Ex-smoker (quit 2 years ago)
• No DM / HTN / Thyroid disorder

---

ASSESSMENT

---

PROBLEM LIST

1. Peripheral neuropathy — etiology to be established
2. Inflammatory small joint disease — to be confirmed
3. Bronchial asthma — on active treatment
4. Sleep disturbance
5. Polypharmacy with interaction risk
6. Low BP on Losartan — monitor

---

CURRENT MEDICATIONS & RATIONALE

---

SIDE EFFECTS & ADVERSE EFFECTS SUMMARY

---

DRUG-DRUG INTERACTIONS

---

INVESTIGATIONS ADVISED

To establish neuropathy etiology:

• CBC, ESR, CRP
• Fasting blood glucose, HbA1c
• Serum Vitamin B12, Folate
• TSH, T3/T4
• Renal function tests (Sr. Creatinine, BUN)
• Liver function tests
• Nerve Conduction Study (NCS/EMG)

To evaluate joint involvement:

• RA Factor
• Anti-CCP antibody
• Serum Uric Acid
• X-ray — right hand (fingers), right knee/ankle

Cardiac/safety monitoring:

• ECG (baseline — doxophylline + ondansetron QT risk)
• Serum electrolytes (K+, Mg2+)
• Daily BP monitoring (Losartan at low BP)

---

PLAN

1. Continue IV Optineuron — reassess response at 5-7 days
2. Confirm indication for Ceftriaxone — if no active infection, consider stopping
3. Monitor BP daily — if BP falls below 100/60, review Losartan dose
4. Limit duration of Chlordiazepoxide — taper plan after discharge; avoid dependence
5. Asthma — assess control, review nebulization frequency, step-down if controlled
6. Send investigations listed above before discharge
7. Counsel patient — no alcohol, no self-medication, smoking cessation reinforcement

---

RED FLAGS — ESCALATE IMMEDIATELY IF:

• 🔴 Severe diarrhea → C. difficile (Ceftriaxone + PPI)
• 🔴 Palpitations / arrhythmia → Doxophylline toxicity or Salbutamol excess
• 🔴 Seizures → Doxophylline toxicity / Benzodiazepine withdrawal
• 🔴 BP drops below 90/60 → Losartan-related hypotension
• 🔴 Urinary retention → Anticholinergic burden (Ipratropium + Chlordiazepoxide)
• 🔴 Acute bronchospasm worsening → Paradoxical bronchospasm
• 🔴 Signs of angioedema (lip/tongue swelling) → Losartan reaction

---

SUGGESTIONS TO DOCTORS

1. Rationalize polypharmacy — confirm each drug's continued indication daily
2. Establish diagnosis first — targeted treatment is safer than empirical multi-drug approach
3. Plan Librium exit strategy — short-term use only; document intended duration
4. Add probiotic alongside antibiotic to reduce C. difficile and GI side effect risk
5. Avoid adding quinolones or macrolides to this prescription without reviewing doxophylline dose
6. Consider neuropathic pain-specific agents (Pregabalin/Duloxetine/Gabapentin) if B12 supplementation alone is insufficient
7. Discharge summary should include follow-up for NCS, RA workup, and BP review

---

⚠️ This ward-round note is for clinical academic and educational purposes. All management decisions must be made by the treating physician.

What you can do

1) Medication reconciliation and indication check

• Verify each drug has a current indication (especially ceftriaxone, losartan, librium).
• Clarify duration for temporary drugs (IV PPI, ondansetron, librium, antibiotic).
• Ensure paracetamol cancellation is documented clearly.

2) Build a drug therapy problem (DTP) list

• Unclear indication: ceftriaxone
• Safety: librium sedation/dependence risk
• Interaction: doxophylline + salbutamol (tachycardia), librium + levocetirizine (sedation)
• Monitoring needed: losartan (BP/K+/SCr), doxophylline toxicity signs
• Possible undertreatment: neuropathic pain may need targeted oral agent if persistent

3) Recommend monitoring parameters

• Daily: BP, pulse, sedation score, bowel pattern, wheeze frequency
• Every 48-72 h (or per protocol): SCr, K+, Mg2+, ECG if palpitations/QT risk
• Symptom tracking: neuropathic pain score (NRS), sleep quality, functional status

4) Prevent and manage ADRs

• Counsel team to watch red flags:
  • severe diarrhea (C. difficile)
  • palpitations/tremor/insomnia (xanthine + beta-agonist excess)
  • excessive drowsiness/confusion (CNS additive effect)
• Suggest early de-escalation when stable (IV to oral switch, stop PRN antiemetic if no nausea).

5) Optimize asthma pharmacotherapy

• Check if current regimen aligns with guideline-based controller strategy.
• Assess inhaler/nebulization technique and adherence.
• Encourage step-down once control is achieved, avoid unnecessary chronic xanthine exposure.

6) Support diagnostic workup for root cause

• HbA1c/FBS, B12, TSH, CBC, ESR/CRP, renal/liver profile
• RA factor/anti-CCP if inflammatory arthritis suspected
• NCS if neuropathy persists

7) Patient counseling (high-impact)

• Avoid alcohol/CNS depressants with librium.
• Report dizziness, severe sedation, palpitations, black stools, severe diarrhea.
• Asthma action points: when to use nebulization and when to seek urgent care.
• Adherence, timing, and not stopping chronic meds abruptly.

8) Discharge pharmaceutical care plan

• Provide a simplified med chart (dose, timing, purpose).
• Mention stop dates for short-course medicines.
• Include follow-up tests and warning symptoms.
• Perform follow-up call in 3-7 days if your setup allows.

---

Ready-to-present Pharm D note (short format)

PHARM D CASE RECORD

SOAP NOTE + PHARMACEUTICAL INTERVENTION SHEET

---

SUBJECTIVE (S)

• Stiffness in fingers (right hand)
• Pain in right leg
• Burning sensation in both lower legs and feet × 1 year
• Tingling and numbness in bilateral feet
• Symptoms worse at night
• Decreased sleep

• K/C/O bronchial asthma × 1 year — on medication
• N/K/C/O DM / HTN / Thyroid disorder
• Ex-smoker — quit 2 years back
• Normal diet and appetite
• Surgical history — insignificant
• Allergic history — to be clarified with patient/physician

---

OBJECTIVE (O)

• CBC, ESR, CRP
• FBS / HbA1c
• Serum B12, Folate
• TSH, T3/T4
• RFT (Sr. Creatinine, BUN)
• LFT
• Serum Electrolytes (K+, Mg2+)
• ECG
• RA Factor, Anti-CCP, Uric Acid
• X-ray right hand and right lower limb
• NCS/EMG (if neuropathy persists)

---

ASSESSMENT (A)

Working Diagnoses:

---

Drug Therapy Problems (DTPs):

---

PLAN (P)

Pharmaceutical Care Interventions:

Immediate (Day 1-2):

1. Clarify antibiotic indication with treating physician
   • If no confirmed infection/culture report → recommend review and possible discontinuation
   • Document allergy history clearly before continuing ceftriaxone
2. Flag CNS sedation risk to medical team
   • Triple sedation: Librium + Levocetirizine + Ondansetron
   • Recommend dose timing adjustment — stagger sedating drugs
   • Advise patient on fall precautions and avoid driving/machinery
3. Request baseline ECG — QT monitoring for ondansetron + doxophylline combination
4. Monitor BP twice daily — if BP falls below 100/60 mmHg, recommend physician review of Losartan dose

Short Term (Day 3-5):

1. Librium exit planning — discuss with physician:
   • Intended duration (short-term only)
   • Tapering schedule before discharge
   • Avoid abrupt discontinuation (seizure risk)
2. Electrolyte monitoring — serum K+, Mg2+ every 48h
   • Hypokalemia risk: salbutamol + doxophylline
   • Hypomagnesemia: pantoprazole long-term
3. Asthma review:
   • Assess frequency of nebulization use
   • Check inhaler technique
   • Ensure budesonide rinse/gargle after nebulization (prevent oral candidiasis)
4. Add probiotic — suggest to physician
   • Concurrent ceftriaxone + pantoprazole increases C. difficile risk
   • Lactobacillus-based probiotic (2hrs apart from antibiotic)

Before Discharge:

1. IV to oral step-down plan:
   • Pantoprazole IV → oral Tab. Pantoprazole 40mg OD once tolerating orally
   • Ondansetron IV → oral/as needed once nausea controlled
   • Ceftriaxone → review need; if continuing, assess oral switch appropriateness
2. Neuropathy reassessment:
   • If B12 levels confirmed low → continue Methylcobalamin and add oral Methylcobalamin 500mcg TID on discharge
   • If B12 normal → broaden workup (NCS, RA workup, inflammatory panel)
   • If pain persists → suggest Pregabalin/Duloxetine/Gabapentin to physician per neuropathic pain guidelines
3. Discharge medication counseling (see counseling section below)

---

MONITORING PARAMETERS

---

PATIENT COUNSELING RECORD

Medications:

Lifestyle counseling:

• Reinforce complete smoking cessation (already quit — positive reinforcement)
• Maintain normal nutrition — ensure adequate B12-rich foods (eggs, dairy, meat)
• Fall prevention — especially at night (dizziness from Losartan + sedation from Librium)
• Sleep hygiene — fixed sleep schedule; Librium is not a long-term sleep solution
• Report any new symptoms — rash, swelling of lips/tongue, severe diarrhea, chest pain, severe dizziness

---

RED FLAGS — COUNSEL PATIENT AND INFORM TEAM

---

PHARMACEUTICAL CARE OUTCOME GOALS

---

PHARM D SIGNATURE BLOCK

---

⚠️ This pharmaceutical care plan is prepared for academic/clinical training purposes. All interventions must be communicated and approved by the treating physician before implementation.